Conceptually, a compound like SM875 capable of selectively promoting the degradation of PrP by targeting a folding intermediate could be the ideal candidate to tackle prion diseases pharmacologically, and possibly synergize with other PrP-silencing strategies. The gene discussed is PRNP; the disease is prion disease.